The Food and Drug Administration issued a drug safety communication Monday requiring manufacturers of Ozempic, Wegovy, Mounjaro, and Zepbound to add warnings about non-arteritic anterior ischemic optic neuropathy. This rare condition causes restricted blood flow to the optic nerve, leading to swelling, cell death, and abrupt vision loss that is often permanent. The agency concluded there is an "increased risk of rare NAION events" in people taking these medications after reviewing reports and studies. I find this regulatory move necessary because the potential for permanent damage demands clear labeling, even if the overall incidence remains low. The specific eye condition affects between two and 10 people per 100,000 in the general population according to the American Academy of Ophthalmology. These small numbers make it difficult to determine with certainty if a direct connection exists between the drugs and the disorder.
Evidence and industry response
Harvard University researchers published a study in JAMA Ophthalmology in 2024 suggesting a link between semaglutide use and higher rates of NAION. In their analysis of 710 patients with diabetes and 979 patients with overweight or obesity, they found that those taking GLP-1 drugs had significantly higher rates of the eye condition after 36 months compared to those using non-GLP-1 alternatives. Among diabetes patients, 8.9 percent of those on semaglutide developed NAION while only 1.8 percent in the control group did so. Similarly, among patients with overweight or obesity, 6.7 percent on a GLP-1 had the condition compared with 0.8 percent in the non-GLP-1 group. However, the study had significant limitations because all patients came from one referral center that treated most regional cases, creating selection bias that makes results hard to generalize. The research also failed to account for diabetes severity or identify a biological mechanism for how the drugs might cause the nerve damage.
Novo Nordisk stated that the data "do not establish a cause-and-effect relationship," reflecting skepticism about the causal link despite the FDA’s conclusion. The American Academy of Ophthalmology noted that any added risk appears small and has not been established as caused by these medications. They advised patients not to stop their medication without talking to a doctor but to see an ophthalmologist promptly if they notice sudden, painless vision loss in one eye. There is no known treatment to reverse the vision loss caused by NAION, which is the most common cause of acute optic nerve injury in people over 50 years old. Risk factors like diabetes, cardiovascular disease, high blood pressure, and obstructive sleep apnea are common among GLP-1 users, further complicating the assessment of causality. I believe the warning label is the correct step forward given the uncertainty, ensuring patients are informed about a potential risk without discouraging effective treatments for serious conditions.
